Author Archives: Natalie Themm
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System
Carterra technology will allow Ordaōs to accelerate its mission of leveraging advanced technologies to efficiently and effectively design novel life-changing therapies for patients in need.
Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research
SALT LAKE CITY, UT, February 22, 2024 (BusinessWire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony […]
Nomi Health Announces Advisory Board to Guide Integrated Care Programs, Closing Gaps in Care for Patients Served by Payers and Providers
Company Introduces Success Care to Tackle Substance Use Disorder Treatment
Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees
Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment
Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership
Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability
Utah Legislative Recap – February 15, 2024
Utah Legislative Recap – Updated February 15, 2024
Eris Biotech accepted to Y Combinator
Eris Biotech accepted to Y Combinator
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)
